Sensei Biotherapeutics (SNSE) Stock Analysis: AI Score & Alternative Data
SNSE alt-data: business outlook climbing, web traffic lagging
Is Sensei Biotherapeutics a buy right now? The alternative data leans yes. This SNSE stock analysis is built on the 25+ alternative data signals AltIndex tracks on Sensei Biotherapeutics every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 62/100: a Buy. The stock trades at $13.85 with a $17M market cap.
What’s driving the buy signal over the past 90 days: 100% of employees are positive on the business outlook. The watch-item: web traffic down 35.5% to 4K monthly visits.
SNSE’s broader alt-data profile also covers headcount (16 employees, according to LinkedIn), X followers (284), and sentiment (100/100). Every signal links to its own page with full history, the SNSE technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on SNSE is just below.
Sensei Biotherapeutics AI Stock Analysis
Sensei Biotherapeutics is a biotechnology company focused on developing innovative immunotherapies for cancer treatment. Their pipeline includes several promising candidates in various stages of development. The company leverages its proprietary platform to identify and target neoantigens, aiming to enhance the effectiveness of cancer immunotherapy.
Analysis generated October 3, 2026.
Recent Sensei Biotherapeutics Stock Alerts
|
Sensei Biotherapeutics | July 20 Employee Rating is down by 4.4% over the last month. |
|
Sensei Biotherapeutics | June 26 Insider Alert: STEPHENSON BRIAN C is buying shares |
|
Sensei Biotherapeutics | June 15 Price is up by 15.9% in the last 24h. |
|
Sensei Biotherapeutics | June 12 Price is up by 7.5% in the last 24h. |
Sensei Biotherapeutics Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 4K | 35.5% | |
| Job Posts | 0 | N/A | |
| LinkedIn Employees | 16 | 0% | |
| Employee Recommend | 85 | 7.6% | |
| Business Outlook | 100 | 0% | |
| Sentiment | 100 | 0% | |
| Reddit Mentions | 0 | N/A | |
| X Mentions | 1 | 0% | |
| Stocktwits Mentions | 0 | N/A | |
| News Mentions | 0 | N/A | |
| Stocktwits Subscribers | 2K | 3.5% | |
| X Followers | 284 | 0% |
About Sensei Biotherapeutics (SNSE)
Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company, is dedicated to the discovery and development of therapies with an initial focus on cancer treatments. The company is headquartered in Rockville, Maryland.
| Price | $13.85 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $17M |
| Year Range | $8 – $35 |
| Dividend Yield | 0% |
| PE Ratio | — |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest Sensei Biotherapeutics News
View more →
Sensei Biotherapeutics (SNSE): Best Performing NASDAQ Stocks According to Wall Street AnalystsMay 5 - Yahoo Entertainment |
|
 |
SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trialMay 31 - Nature.com |
"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming TherapiesMay 14 - GlobeNewswire |
|
See Sensei Biotherapeutics’s complete price and AI Score history
Sign up to unlock 1-year and all-time charts for SNSE, plus 25+ alternative data signals, AI Scores, and real-time alerts.
Get Started for FREESensei Biotherapeutics Earnings & Financial Performance
View all earnings →Sensei Biotherapeutics Insider Trading Activity
View all →| STEPHENSON BRIAN C filed to sell 33,054 shares at $0.0. Jun 26 '26 |
| STEPHENSON BRIAN C filed to sell 27,384 shares at $0.0. Jun 26 '26 |
| STEPHENSON BRIAN C filed to sell 32,954 shares at $0.0. Jun 26 '26 |
| STEPHENSON BRIAN C filed to sell 31,596 shares at $0.0. Jun 26 '26 |
| STEPHENSON BRIAN C filed to sell 20,304 shares at $0.0. Jun 24 '26 |
Sensei Biotherapeutics Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to Sensei Biotherapeutics
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
Actuate TherapeuticsACTU |
$0.68 6.2% | $17M | 56 |
 |
Bionano GenomicsBNGO |
$1.46 0.0% | $17M | 39 |
 |
Dyadic InternationalDYAI |
$0.44 2.7% | $18M | 53 |
 |
Dare BioscienceDARE |
$0.77 2.3% | $16M | 57 |
 |
Jasper TherapeuticsJSPR |
$0.56 1.7% | $19M | 53 |
Explore Sensei Biotherapeutics Data
Frequently Asked Questions: Sensei Biotherapeutics (SNSE)
Sensei Biotherapeutics has an AltIndex AI Score of 62/100 (Buy). The score reflects positive alternative data signals. All investments carry risk.
62/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Sensei Biotherapeutics (SNSE) stock is $13.85 with a market cap of $17M.
As of today, Sensei Biotherapeutics’s PE (Price to Earnings) ratio is —.
View the latest Sensei Biotherapeutics insider transactions to see recent buying and selling activity by company executives and directors.
Check the Sensei Biotherapeutics congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The SNSE stock price chart above shows Sensei Biotherapeutics’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Sensei Biotherapeutics technical analysis for RSI, moving averages, and more.
See the stocks similar to Sensei Biotherapeutics section on this page for companies in the same industry ranked by market cap and AI Score.
